10 New Drugs for Primary Care: Q4 2019

Better CV Health in Early Pregnancy Offsets High Genetic Risk: Daily Dose

Slideshow

Two first-in-class migraine drugs, the first generic version of NuvaRing®, and 7 more fourth quarter FDA-approved drugs for primary care.

While 2019 may be over, numerous medications were approved by the US Food and Drug Administration (FDA) during the fourth quarter of 2019 for conditions often seen in primary care.Below, you will find details on the first and only FDA-approved oralÂ calcitonin gene-related peptide receptor antagonist for the treatment of migraine; the firstÂ topical minocycline to be approved for any condition; the first generic version of NuvaRingÂ®;Â and 7 more.Â

Related Content

September 27th 2024

Gepants for Migraine Prevention: A Perfect Fit for Primary Care

Your daily dose of the clinical news you may have missed.

March 30th 2022

Roflumilast Cream 0.15% Leads to Consistent Improvements in Atopic Dermatitis Across Diverse Skin Types

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with headache specialist Peter McAllister, MD.

September 25th 2024

Primary Viewpoints Episode 3: The Challenges of Hypertension Management

Roflumilast cream 0.15% was associated with consistent and meaningful improvements in AD clearance and itch reduction, according to new data.

September 30th 2020

FDA Accepts NDA for Delgocitinib Cream, Developed Specifically to Treat Chronic Hand Eczema

In episode 3 of Primary Viewpoints, Brigham and Women's hypertension expert Naomi Deirdre Fisher, MD, discusses the challenges of hypertension management in primary care.

Grace Halsey

FDA Approves Lebrikizumab-lbkz for Moderate to Severe AD: Daily Dose

Delgocitinib specifically inhibits activation of JAK-STAT signaling in chronic hand eczema and would be an option for people unable to use topical corticosteroids.

Better CV Health in Early Pregnancy Offsets High Genetic Risk: Daily Dose

Your daily dose of the clinical news you may have missed.

Related Content

September 27th 2024

Gepants for Migraine Prevention: A Perfect Fit for Primary Care

Your daily dose of the clinical news you may have missed.

March 30th 2022

Roflumilast Cream 0.15% Leads to Consistent Improvements in Atopic Dermatitis Across Diverse Skin Types

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with headache specialist Peter McAllister, MD.

September 25th 2024

Primary Viewpoints Episode 3: The Challenges of Hypertension Management

Roflumilast cream 0.15% was associated with consistent and meaningful improvements in AD clearance and itch reduction, according to new data.

September 30th 2020

FDA Accepts NDA for Delgocitinib Cream, Developed Specifically to Treat Chronic Hand Eczema

In episode 3 of Primary Viewpoints, Brigham and Women's hypertension expert Naomi Deirdre Fisher, MD, discusses the challenges of hypertension management in primary care.

Grace Halsey

FDA Approves Lebrikizumab-lbkz for Moderate to Severe AD: Daily Dose

Delgocitinib specifically inhibits activation of JAK-STAT signaling in chronic hand eczema and would be an option for people unable to use topical corticosteroids.